105990-27-0
105990-27-0 結(jié)構(gòu)式
基本信息
中文別名
(S)-(-)-去甲烏藥堿氫溴酸鹽 英文別名
(-)-Higenamine hydrobromide(S)-(-)-HigenaMine HydrobroMide
(S)-(-)-Norcoclaurine hydrobromide
(1S)-1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol:hydrobromide
(1S)-1,2,3,4-Tetrahydro-1-[(4-hydroxyphenyl)methyl]-6,7-isoquinolinediol hydrobromide (1:1)
(S)-(-)-去甲烏藥堿氫溴酸鹽價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/05/22 | HY-N2037C | (S)-(-)-去甲烏藥堿氫溴酸鹽 (S)-Higenamine hydrobromide | 105990-27-0 | 1mg | 3450元 |
常見(jiàn)問(wèn)題列表
生物活性
(S)-Higenamine ((S)-Norcoclaurine) hydrobromide，Higenamine 的 S 型異構(gòu)體，是芐基異喹啉生物堿生物合成的起始化合物，由去甲月桂堿合酶 (NCS) 將多巴胺和 4-羥基苯乙醛 (4-HPAA) 縮合生成。靶點(diǎn)
|
Human Endogenous Metabolite
|
體外研究
The biosynthetic pathway leading to benzylisoquinoline alkaloids originates from the enzyme-catalyzed condensation of dopamine and 4-hydrophenylacetaldehyde to yield (S)-norcoclaurine. Both substrates are secondary metabolites derived from the decarboxylation/hydroxylation/deamination of tyrosine.